scholarly journals Outcome of Percutaneous Transluminal Angioplasty in Diabetic Patients with Critical Limb Ischaemia

2014 ◽  
Vol 122 (01) ◽  
pp. 50-54 ◽  
Author(s):  
J. An ◽  
Y.-M. Jang ◽  
K.-H. Song ◽  
S. Kim ◽  
S. Park ◽  
...  
Keyword(s):  
Percutaneous Transluminal Angioplasty ◽  
Transluminal Angioplasty ◽  
Critical Limb Ischaemia ◽  
Diabetic Patients ◽  
Limb Ischaemia ◽  
Percutaneous Transluminal

scholarly journals The clinical course of critical limb ischaemia and the role of endovascular revascularisation in patients with diabetes

2015 ◽  
Vol 18 (3) ◽  
pp. 57-69 ◽  
Author(s):  
Olga Nikolaevna Bondarenko ◽  
Gagik Radikovich Galstyan ◽  
Ivan Ivanovich Dedov
Keyword(s):  
Percutaneous Transluminal Angioplasty ◽  
Disease Process ◽  
Transluminal Angioplasty ◽  
Critical Limb Ischaemia ◽  
Diabetic Patients ◽  
Limb Ischaemia ◽  
Clinical Effects ◽  
Primary Therapy ◽  
Patients With Diabetes ◽  
Percutaneous Transluminal

Recent data suggest that chronic critical limb ischaemia (CLI) is the most important reason for amputation among diabetic patients. The high prevalence of CLI in this patient group is associated with specific clinical and morphological properties of peripheral arterial disease. Percutaneous transluminal angioplasty is an appropriate primary therapy, but it is not considered early in the disease process, and is instead reserved as a limb salvage strategy. Low primary patency, despite optimal clinical effects, remains a typical issue of percutaneous transluminal angioplasty for diabetic patients in particular. Thus, the indications, technical success and clinical results of endovascular revascularisation need to be clarified in patients with diabetes. Although difficult, the procedure can be effective through a multidisciplinary approach.

scholarly journals Percutaneous transluminal angioplasty for lower limb ischaemia

1999 ◽  
Vol 86 (5) ◽  
pp. 704-704 ◽  
Author(s):  
J. Brittenden ◽  
G. C. Beattie ◽  
I. Gillespie ◽  
K. McBride ◽  
G. McInnes ◽  
...  
Keyword(s):  
Lower Limb ◽  
Percutaneous Transluminal Angioplasty ◽  
Transluminal Angioplasty ◽  
Limb Ischaemia ◽  
Lower Limb Ischaemia ◽  
Percutaneous Transluminal

Percutaneous transluminal angioplasty for critical limb ischemia in very elderly diabetic patients

2013 ◽  
Vol 25 (2) ◽  
pp. 225-228 ◽  
Author(s):  
Carmine Gazzaruso ◽  
Adriana Coppola ◽  
Silvia Collaviti ◽  
Cesare Massa Saluzzo ◽  
Federica Furlani ◽  
...  
Keyword(s):  
Critical Limb Ischemia ◽  
Percutaneous Transluminal Angioplasty ◽  
Limb Ischemia ◽  
Transluminal Angioplasty ◽  
Diabetic Patients ◽  
Very Elderly ◽  
Percutaneous Transluminal

scholarly journals Difference in Serum Endostatin Levels in Diabetic Patients with Critical Limb Ischemia Treated by Autologous Cell Therapy or Percutaneous Transluminal Angioplasty

2018 ◽  
Vol 27 (9) ◽  
pp. 1368-1374
Author(s):  
Andrea Nemcova ◽  
Alexandra Jirkovska ◽  
Michal Dubsky ◽  
Libor Kolesar ◽  
Robert Bem ◽  
...  
Keyword(s):  
Cell Therapy ◽  
Percutaneous Transluminal Angioplasty ◽  
Limb Ischemia ◽  
Transluminal Angioplasty ◽  
Angiogenic Factor ◽  
Diabetic Patients ◽  
Autologous Cell ◽  
Potential Marker ◽  
Autologous Cell Therapy ◽  
Percutaneous Transluminal

The aim of this study was to compare the serum levels of the anti-angiogenic factor endostatin (S-endostatin) as a potential marker of vasculogenesis after autologous cell therapy (ACT) versus percutaneous transluminal angioplasty (PTA) in diabetic patients with critical limb ischemia (CLI). A total of 25 diabetic patients with CLI treated in our foot clinic during the period 2008–2014 with ACT generating potential vasculogenesis were consecutively included in the study; 14 diabetic patients with CLI who underwent PTA during the same period were included in a control group in which no vasculogenesis had occurred. S-endostatin was measured before revascularization and at 1, 3, and 6 months after the procedure. The effect of ACT and PTA on tissue ischemia was confirmed by transcutaneous oxygen pressure (TcPO2) measurement at the same intervals. While S-endostatin levels increased significantly at 1 and 3 months after ACT (both P < 0.001), no significant change of S-endostatin after PTA was observed. Elevation of S-endostatin levels significantly correlated with an increase in TcPO2 at 1 month after ACT ( r = 0.557; P < 0.001). Our study showed that endostatin might be a potential marker of vasculogenesis because of its significant increase after ACT in diabetic patients with CLI in contrast to those undergoing PTA. This increase may be a sign of a protective feedback mechanism of this anti-angiogenic factor.

Sign in / Sign up

Export Citation Format

Share Document